Enovis (ENOV) Short-term Investments (2017 - 2022)

Enovis' (ENOV) quarterly Short-term Investments came in at $200.3 million in Q3 2022, down 23.87% on a QoQ basis from $263.1 million in Q3 2022.

Enovis (ENOV) Short-term Investments (2017 - 2022) Analysis & Trends

Enovis (ENOV) has 2 years of Short-term Investments data on file, last reported at $200.3 million in Q3 2022.

On a quarterly basis, Short-term Investments changed N/A year-over-year to $200.3 million in Q3 2022; TTM through Sep 2022 was $200.3 million, a N/A change from a year earlier, with the FY2017 full-year figure at $149.6 million, changed N/A from the prior year.
Short-term Investments for Q3 2022 stood at $200.3 million, down from $263.1 million in the prior quarter.
Over the last five years, Short-term Investments for ENOV reached as high as $263.1 million in Q3 2022 and fell as low as $200.3 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Enovis	1.50 Bn	1.47 Bn	365.49 Mn

Download Data